Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

OBJECTIVES: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab is the only immunotherapy to significantly improve overall survival (OS) versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Saba, Nabil F., Blumenschein, George, Guigay, Joel, Licitra, Lisa, Fayette, Jerome, Harrington, Kevin J., Kiyota, Naomi, Gillison, Maura L., Ferris, Robert L., Jayaprakash, Vijayvel, Li, Li, Brossart, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723820/
https://www.ncbi.nlm.nih.gov/pubmed/31422216
http://dx.doi.org/10.1016/j.oraloncology.2019.06.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723820/
https://www.ncbi.nlm.nih.gov/pubmed/31422216
http://dx.doi.org/10.1016/j.oraloncology.2019.06.017

Ejemplares similares